ByteDance's Anew Labs presents first AI-designed therapy as TikTok parent enters drug discovery race
Summary
ByteDance's drug unit showed an AI-designed IL-17 inhibitor at a Boston conference. The molecule targets interactions pharma called undruggable. Only trials wil...
Original reporting
Open original sourceAFBytes is a read-only aggregator. Use the original source for full context and complete reporting.